Vinflunine + capecitabine

Vinflunine + capecitabine is a combination chemotherapy regimen used primarily in the treatment of metastatic or locally advanced breast cancer, particularly in patients who have previously been treated with anthracyclines and taxanes. Vinflunine is a synthetic vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis and inducing apoptosis in rapidly dividing cancer cells. Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within tumor tissues; 5-FU acts as an antimetabolite, inhibiting thymidylate synthase and interfering with DNA synthesis. The combination has demonstrated modest improvements in progression-free survival compared to capecitabine alone, with manageable toxicity profiles dominated by hematological (notably neutropenia) and gastrointestinal side effects[2][6]. This regimen has been studied for use after failure of prior standard chemotherapies[2][6].

Other names

vinfluninecapecitabine